Intech Investment Management LLC Trims Position in Abbott Laboratories $ABT

Key Points

• Intech Investment Management cut its Abbott Laboratories stake by 19.4% in the fourth quarter, selling 22,265 shares and leaving it with 92,796 shares valued at about $11.6 million.
• Insider activity was mixed: SVP Eric Shroff sold 709 shares, while Director Daniel J. Starks bought 10,000 shares, indicating both some profit-taking and continued insider confidence.
• Abbott reported solid quarterly results, with EPS of $1.15 beating estimates and revenue of $11.16 billion topping forecasts; the company also raised FY2026 and Q2 2026 guidance.

Intech Investment Management LLC trimmed its position in Abbott Laboratories (NYSE:ABT - Free Report) by 19.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,796 shares of the healthcare product maker's stock after selling 22,265 shares during the period. Intech Investment Management LLC's holdings in Abbott Laboratories were worth $11,626,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABT. Freemont Management S.A. grew its stake in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock worth $1,341,000 after acquiring an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth $116,580,000. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of Abbott Laboratories in the third quarter worth $185,640,000. Thrivent Financial for Lutherans grew its stake in shares of Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock worth $30,931,000 after acquiring an additional 48,286 shares during the last quarter. Finally, AE Wealth Management LLC grew its stake in shares of Abbott Laboratories by 20.8% in the third quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker's stock worth $8,774,000 after acquiring an additional 11,264 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company's stock, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company's stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last 90 days. Insiders own 0.46% of the company's stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott recently secured FDA and EU approval for its AI-powered Ultreon 3.0 tool, which could support growth in its cardiovascular imaging business and add to its medical technology momentum. Article Title
• Positive Sentiment: Abbott also obtained CE mark clearance for its Libre Duo glucose-ketone monitor, expanding its diabetes technology lineup and reinforcing innovation in one of its key growth categories. Article Title
• Neutral Sentiment: Recent coverage highlighting strong Wall Street views on Abbott suggests analysts remain constructive on the stock’s long-term prospects, but the articles do not point to a new upgrade or a near-term earnings catalyst. Article Title
• Neutral Sentiment: Zacks noted that investors have been searching for Abbott more heavily, which can reflect increased interest, but does not by itself change the company’s fundamentals. Article Title
• Negative Sentiment: One comparison piece argued Boston Scientific may offer more upside than Abbott, which can weigh on ABT sentiment by implying investors may prefer a rival medtech name right now. Article Title

Abbott Laboratories Trading Down 1.1%

Shares of NYSE:ABT opened at $85.36 on Friday. The company has a market cap of $148.68 billion, a P/E ratio of 23.91, a PEG ratio of 1.44 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The stock's fifty day moving average price is $94.46 and its 200-day moving average price is $110.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company's quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ABT. Argus cut their target price on Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 21st. Barclays cut their target price on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research note on Monday, April 20th. Evercore cut their target price on Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. UBS Group cut their target price on Abbott Laboratories from $158.00 to $135.00 and set a "buy" rating on the stock in a research note on Monday, April 20th. Finally, Jefferies Financial Group lowered their price target on Abbott Laboratories from $145.00 to $135.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $119.09.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.